

Curcumin: A new candidate for melanoma therapy?

Hamed Mirzaei^{1*}, Gholamreza Naseri^{2*}, Ramin Rezaee³, Mohsen Mohammadi⁴, Zarrin Banikazemi⁵, Hamid Reza Mirzaei⁶, Hossein Salehi⁷, Mostafa Peyvandi^{8,9}, John M. Pawelek¹⁰ and Amirhossein Sahebkar¹¹

¹ Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

² Department of Anatomical Sciences, Golestan University of Medical Sciences, Gorgan, Iran

³ Department of Physiology and Pharmacology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran

⁴ Razi Herbal Medicines Research Center and Department of pharmaceutical biotechnology, Faculty of pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran

⁵ Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran

⁶ Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁷ Department of Anatomical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁸ Department of Anatomical Sciences, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

⁹ Department of Anatomical Sciences, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran

¹⁰ Department of Dermatology and the Yale Cancer Center, Yale University School of Medicine, New Haven, CT

¹¹ Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Melanoma remains among the most lethal cancers and, in spite of great attempts that have been made to increase the life span of patients with metastatic disease, durable and complete remissions are rare. Plants and plant extracts have long been used to treat a variety of human conditions; however, in many cases, effective doses of herbal remedies are associated with serious adverse effects. Curcumin is a natural polyphenol that shows a variety of pharmacological activities including anti-cancer effects, and only minimal adverse effects have been reported for this phytochemical. The anti-cancer effects of curcumin are the result of its anti-angiogenic, pro-apoptotic and immunomodulatory properties. At the molecular and cellular level, curcumin can blunt epithelial-to-mesenchymal transition and affect many targets that are involved in melanoma initiation and progression (e.g., BCL2, MAPKS, p21 and some microRNAs). However, curcumin has a low oral bioavailability that may limit its maximal benefits. The emergence of tailored formulations of curcumin and new delivery systems such as nanoparticles, liposomes, micelles and phospholipid complexes has led to the enhancement of curcumin bioavailability. Although *in vitro* and *in vivo* studies have demonstrated that curcumin and its analogues can be used as novel therapeutic agents in melanoma, curcumin has not yet been tested against melanoma in clinical practice. In this review, we summarized reported anti-melanoma effects of curcumin as well as studies on new curcumin formulations and delivery systems that show increased bioavailability. Such tailored delivery systems could pave the way for enhancement of the anti-melanoma effects of curcumin.

Plant extracts and their active compounds have long been regarded as promising candidates to treat a variety of human diseases; however, natural products or their synthetic analogues may cause serious side-effects.^{1,2} Since natural products generally show less toxicity than synthetic compounds, they have been the subject of increasing research interest particularly for the treatment of cancer and its complications.^{3,4} Curcumin is a natural polyphenol extracted from the rhizomes of the plant *Curcuma longa* L (turmeric).^{5,6} Mounting evidence

indicates that curcumin plays significant roles in several biological processes and possesses several pharmacological properties which are beneficial to the treatment of human diseases. These pharmacological effects include antioxidant,⁷⁻¹⁰ anti-inflammatory,^{3,11-13} lipid-modifying,¹⁴⁻¹⁷ anti-arthritis,^{10,18} cardio-protective,^{19,20} anti-ischemic,²¹ anti-depressant,^{6,22} anti-diabetic,²³ neuro-protective,²⁴ cognition-enhancing²⁵⁻²⁸ and anti-atherosclerotic^{5,29} properties. These studies confirmed that curcumin can affect various targets such as cytokines, protein kinases, multiple transcription factors, adhesion molecules, inflammatory mediators and redox state enzymes.^{5,30}

Melanoma arises from malfunctioning of normal melanocytes in the epidermis. In recent decades, the incidence of melanomas has increased at an alarming rate, particularly in Western populations where individuals tend to have lighter skin color and thus less sun protection.³¹⁻³³ Patients with advanced malignancies have poor prognoses with average survival times of 3–11 months.³¹ Many melanomas with early diagnoses can be removed by surgical resection with no further problems to the patient. However, melanomas

Key words: curcumin, melanoma, therapy, cancer

*H.M and G.N. contributed equally to this work

DOI: 10.1002/ijc.30224

History: Received 9 Jan 2016; Accepted 25 May 2016; Online 9 June 2016

Correspondence to: Amirhossein Sahebkar, Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, P.O. Box: 91779-48564, Iran, Tel.: 985138002288, Fax: 985138002287; E-mail: sahebkar@mums.ac.ir, amir_saheb2000@yahoo.com

notoriously have high metastatic potential, and once metastasis occurs, they are very difficult to treat.^{31,34} Therefore, the search for novel therapies against melanoma is warranted. Many studies introduced curcumin as a novel molecule that can be used for the treatment of melanoma.^{35,36} These reports have employed curcumin and its analogues using various delivery systems in melanoma therapy.^{36,37}

With respect to the pharmacokinetic profile of curcumin, it has been observed that utilization of novel delivery systems such as micelles and nano-particles could increase curcumin bioavailability, thereby potentiating its anti-tumor effects in melanoma. In addition, the expression of certain microRNAs, known to influence many molecular and cellular processes, can be altered by curcumin.^{38,39} This review summarizes the findings of various studies on the utilization of curcumin in melanoma therapy. Research on the tailored formulations with novel drug delivery systems, and synthetic analogues of curcumin are also discussed.

Curcumin as a Therapeutic Agent in Melanoma

For hundreds of years, turmeric has been utilized as a treatment for conditions like inflammation, neoplasm, etc.^{3,5} In recent years, molecular targets and various cellular and molecular pathways that are affected by curcumin have been evaluated and identified.^{5,40}

Several studies on animals and humans have indicated that curcumin can be safe at various doses.^{41,42} These reports showed that curcumin could be tolerated even at very high doses. Although obtaining high doses of curcumin in humans is a problem, with the help of novel drug delivery systems, the problem of using bulky doses could be resolved.⁴³ In addition, various studies have indicated that even low doses of curcumin have therapeutic effects against various diseases.⁴⁴

Low solubility and lack of a high systemic bioavailability is regarded as a major problem in utilization of curcumin as a therapeutic agent.⁴⁵ Several studies have reported low or undetectable plasma/tissue levels of free curcumin.^{46,47} However, it must be taken into account the metabolites and degradation products of curcumin, like curcumin sulfate, curcumin glucuronide and tetrahydrocurcumin possess significant and, in some cases, similar or stronger biological and pharmacological activities compared with curcumin.⁴⁸⁻⁵⁰ Another proof for the activity of curcumin metabolites is the biological activity of curcumin treated with alkali, which is known to destabilize curcumin.⁵¹

Many studies have shown that in multi-factorial diseases such as cancer, some agents that affect various cellular and molecular targets may be of higher therapeutic value.^{5,30,52} Among these agents, curcumin shows suitable properties and can affect different pathways in various diseases such as cancer.^{52,53} Melanoma is known as one of the important malignancies that shows poor diagnosis and high resistance to different treatment regimens. Mounting evidence indicates that curcumin affects several molecular and cellular pathways

involved in melanoma pathogenesis such as MST1, JNK, Foxo3, Bim-1, Mcl-1, Bcl-2, Bax and JAK-2/STAT-3⁵⁴⁻⁵⁶ making it a promising therapeutic agent to be used against this type of cancer. Figure 1 shows various cellular and molecular pathways influenced by curcumin in melanoma.

In a research, Bush *et al.*⁵⁶ investigated the molecular pathways targeted by curcumin during apoptosis in human melanoma cells. They revealed that curcumin can induce cell death in various melanoma cell lines with wild-type or mutant p53. They also showed that curcumin induces apoptosis dose- and time-dependently in melanoma cell lines. Their results indicated that curcumin induced cell death via different pathways *e.g.*, activation of caspases-3 and caspases-8 but not caspase-9 via a membrane-mediated mechanism. In addition, it was shown that curcumin could induce Fas receptor aggregation in a FasL-independent manner.⁵⁶ Previous studies showed that suppression of receptor aggregation inhibited curcumin-induced cell death. Some evidence revealed that melanoma cells with mutant p53 show strong resistance to conventional chemo-therapeutic agents.⁵⁶ Therefore, curcumin might be able to overcome the chemo-resistance of these cells and open new horizons in cancer therapy.

Zhang *et al.*⁵⁷ investigated the effects of curcumin on the migration, proliferation and invasiveness of human melanoma cells. In the referred study, A375 cells were cultured, passaged and treated with different concentrations of curcumin. Different concentrations of curcumin induced significant changes in the morphology of A375 cells. The results indicated that curcumin can significantly inhibit the migration and invasion of A375 cells compared with the control group. Curcumin (50, 25 and 12.5 mM) significantly decreased the number of A375 cells in the treated group. In addition, the rates of apoptosis at the concentrations of 6.25 and 12.5 mM of curcumin were significantly higher than those of the control group. On the other hand, phosphorylation levels of STAT-3 and JAK-2 at the concentrations of 10 and 20 mM of curcumin were significantly lower than those in the control group. Bcl-2 protein expression at the concentrations of 1, 2.5, 5, 10 and 20 mM of curcumin was significantly lower compared with the control group. In this latter study, curcumin showed various effects such as anti-proliferative and pro-apoptotic activities on A375 cells, and the inhibition of JAK-2/STAT-3 signaling pathway was suggested as one of mechanisms through which curcumin exerts its effects on this cell line.⁵⁷

Philip *et al.* showed that osteopontin (OPN) induces nuclear factor kappa B (NF- κ B) through pro-matrix metalloproteinase 2 activation via IkappaB alpha/IKK signaling pathways which are downregulated by curcumin in a melanoma mouse model.⁵⁸ Their results indicated that curcumin could inhibit NF- κ B-DNA binding, NF- κ B transcriptional activity and the OPN-induced translocation of p65. The authors revealed that curcumin could inhibit OPN-induced cell migration, extracellular matrix invasion and cell proliferation. Also, curcumin can synergistically induce apoptotic




Figure 1. Cellular and molecular pathways affected by curcumin in melanoma. MAPK: mitogenactivated protein kinase; STAT: signal transducer and activator of transcription; NF- κ B: nuclear factor kappa-light chain-enhancer of activated B cells; PARP: poly(ADP-ribose) polymerase. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

morphological changes by OPN in melanoma cells. Moreover, curcumin suppresses OPN-induced tumor growth in nude mice, and inhibits the activation of OPN-induced tumor and the levels of pro-MMP-2 expression. Table 1 illustrates the effect of curcumin on melanoma reported by different studies.⁵⁸

An important mediator of the cell stress response is heat shock protein 90 (Hsp90), which has been reported to be upregulated in melanoma,⁵⁹ and its inhibition, along with the inhibition of Hsp70, has been reported to enhance the sensitivity of melanoma cells to the anti-tumor effects of hyperthermia.⁶⁰ Interestingly, there is evidence showing that curcumin synergistically enhances the anti-tumor effect of bortezomib in melanoma through inhibition of Hsp90 expression.⁶¹ Hemeoxygenase/biliverdin reductase (HO/BVR) is another main component of the cell stress response.^{62,63} This system facilitates the degradation of heme which is toxic if produced in excess or unbalanced under redox conditions.⁶⁴ Recently, it was found that HO/BVR system is upregulated in melanoma patients.⁶⁵ Interestingly, among the

pharmacological effects of curcumin, enhancement of the cell stress response was mediated through HO/BVR.⁶⁶ Hence, regulation of cell stress response could be regarded as a potential mechanism curcumin may affect development and progression of melanoma.

Parallel to the identification of many anti-cancer effects of curcumin, some studies have indicated that this agent could cause potential adverse effects under specific conditions.^{67,68} There is some data showing that curcumin could induce chromosomal alterations and DNA damage, both *in vitro* and *in vivo*.⁶⁹ However, Kurien and colleagues indicated that curcumin does not bind or intercalate into DNA.⁷⁰ It should be noted that this binding could be caused by the solvent of curcumin (*e.g.*, organic solvents) rather than the compound itself.⁷⁰ Inhibition of several drug-metabolizing enzymes including CYP3A4, glutathione-S-transferase and UDP and UDP-glucuronyl transferase is another effect of curcumin which may induce potential drug interactions.⁷¹ Although such sporadic reports on the potential adverse effects of curcumin exist and necessitate further evaluations, the trend in

Table 1. Effects of curcumin on melanoma as reported by various studies

Dose	Target gene	Effects	Model (in vitro/in vivo/human)	Type of cell line	Ref
0–80 mM	mPTP	Facilitating mPTP death pathway	<i>In vitro</i>	WM-115, B16	72
10, 20 mM	JAK-2/STAT-3	Anti-proliferative and pro-apoptotic activities	<i>In vitro</i>	A375	57
10 μ M	–	Inhibition of proliferation and stimulation of differentiation	<i>In vitro</i>	B16F10	73
15 μ M	Mcl-1, Bcl-2, Bax, caspase-8, Caspase-3, NF- κ B, p38, p53	Apoptosis induction	<i>In vitro</i>	A375, MV3, M14	74
30–40 μ M	caspase-3/7	Apoptosis induction	<i>In vitro</i>	B16F10	75
10 μ M	ERK/Akt	Apoptosis induction	<i>In vitro</i>	A375	76
30–100 μ M	mPTP, ANT-1	Apoptosis induction	<i>In vitro</i>	WM-115	77
0.2–5 μ g/ml	caspases 8, 9, 3	Apoptosis induction	<i>In vitro</i>	G-361, A375	78
25 μ m/ml	MST1, JNK, Foxo3, Bim-1	Apoptosis induction	<i>In vitro</i>	B16 and WM-115	79
2.5 mM	MRP1, GSTM1	Apoptosis induction	<i>In vitro</i>	CAL1	80
< 5 μ M	–	Decreasing cell growth	<i>In vitro</i>	B16-F10	81
50 μ M	–	Inhibition of tumorigenesis and angiogenesis	<i>In vitro, in vivo</i>	B16F1, B16F10, A375, SK-Mel-28	82
10 ⁻⁵ M	PDE1A	Anti-proliferative effect	<i>In vitro</i>	B16F10	83
20 μ M	–	Inhibition of melanogenesis	<i>In vitro</i>	B16F10	84
50 μ M	NF κ B, MT1-MMP, MMP-2	Inhibition of tumor growth and decrease migration	<i>In vitro, in vivo</i>	B16F10	85
1.25–10 μ M	PI3K/Akt/GSK 3 β , ERK, p38 MAPK	Inhibits melanogenesis	<i>In vitro</i>	B16	86
High dose	–	Apoptosis induction	<i>In vitro</i>	G361, A375	87
100 mg/kg	EphA2, PI3K, MMP-2, MMP9	Inhibition of tumor growth and vasculogenic mimicry	<i>In vitro</i>	B16F10	88
10 μ M	Caspase 3, Caspase 9, Bcl-XL, X-IA	Induce apoptosis	<i>In vitro</i>	B16, WM-115	89
10 μ M	MITF, MEK/ERK, PI3K/Akt	Suppressive activity on α -MSH-stimulated melanogenesis	<i>In vitro</i>	B16F10	90
10–30 μ M	caspase-9, caspase-3	Induce apoptosis	<i>In vitro</i>	M21, SP6.5	55
20 μ M	PRL-3	Inhibition of metastasis	<i>In vitro, in vivo</i>	B16, B16BL6	91
20 μ M	STAT1, STAT5, IFN-alpha, IFN-gamma, interleukin-2	Apoptosis induction	<i>In vitro</i>	A375, Hs294T	92
50 μ M	Akt, NF- κ B, Bcl _{xL} , Erk, VEGF, cyclin D1	Blocks tumor formation	<i>In vitro, in vivo</i>	B16F10	93
–	bcl-2, P53	Apoptosis induction	<i>In vivo</i>	B16	94
75 μ M	elf2 α , GADD 153, aspases-3/7, Bcl-2	Apoptosis induction	<i>In vitro</i>	B16F10	95
50 μ M	COX-2, cyclin D1, NF- κ B	Apoptosis induction	<i>In vivo</i>	B16F10	96

Table 1. Effects of curcumin on melanoma as reported by various studies (Continued)

Dose	Target gene	Effects	Model (in vitro/in vivo/human)	Type of cell line	Ref
30 μ M	c-myc, caspase-3	Apoptosis induction	<i>In vitro</i>	A375	97
6.1–7.7 μ M	NF- κ B, IKK	Antiproliferative and apoptotic	<i>In vitro</i>	C32, G-361, WM 266-	54
30 μ M	GSTP1, MRP1	Inhibition of the multidrug resistance	<i>In vitro</i>	A375	98
18, 27 μ M	–	Inhibition of growth of B16-R melanoma	<i>In vitro, in vivo</i>	B16-R	99
15 μ M	MMP-2	Anti-metastatic	<i>In vitro</i>	B16 F10	100
50 μ M	iNOS, NF- κ B	Apoptosis and cell cycle arrest	<i>In vitro</i>	A375	101
2.6, 1.9 μ M	GST	Inhibition of the multidrug resistance	<i>In vitro</i>	CAL1	102
Dependent manner	Nm23, E-cadherin	Anti-metastatic properties	<i>In vitro, in vivo</i>	B16F10	103
50, 100 μ M	OPN, NF- κ B	Apoptosis induction	<i>In vitro, in vivo</i>	B16F10	58
30 μ M	Caspases-3/8	Apoptosis induction	<i>In vitro</i>	MMAN, MMRU, RPEP, PMWK, Sk-mel-2, Sk-mel-5, Sk-mel-28c, MEWO	56
125 μ g/ml	COX-I, COX-II	Antioxidant and anti-inflammatory activities	<i>In vitro</i>	SKMEL-28, M14, UACC-62	104
25 μ M	GST	Inhibition of the multidrug resistance	<i>In vivo</i>	IGR-39	105
200 nmol/kg	–	Inhibition of lung metastasis	<i>In vivo</i>	B16F10	106

findings is in favor of the acceptable safety of this compound. Moreover, conducted clinical trials of curcumin have shown the safety of curcumin for human use, even in studies administering highly bioavailable preparations of curcumin. It is also interesting to note that curcumin has been affirmed with a GRAS (generally recognized as safe) status by the US Food and Drug Administration.

Curcumin Analogs as Powerful Tools in Melanoma Therapy

Mounting evidence indicates that curcumin has multiple biological effects that make it a promising therapeutic candidate to be used in the treatment of several diseases such as cancer.¹⁰⁷ On the other hand, it was observed that this agent has low oral bioavailability which led to the development of curcumin analogues (such as DM-1, EF24, D6 and CDF) with better anti-cancer effects and bioavailability.⁵² DM-1, one of the curcumin analogues, has shown anti-tumor effects in various *in vitro* and *in vivo* models.^{107,108} It has been confirmed that this compound is not only a suitable anti-cancer agent with anti-metastatic and anti-proliferative activities but also it has minimal side effects on normal cells.^{109, 110} Table 2

shows various curcumin analogues that can be used in melanoma therapy.

Commercial curcuminoids include curcumin, demethoxycurcumin and bisdemethoxycurcumin. Most of the studies assessing the effects of curcumin against melanoma have been conducted with curcumin. Therefore, the impact of demethoxy and bisdemethoxy analogues, which are known to differ with curcumin in some properties,¹¹¹ in reducing the progression of melanoma remains to be clarified. Four major strategies that could be used to improve the pharmacokinetic profile and enhance the delivery of curcumin are (i) Liposomes, micelles and phospholipid complexes; (ii) Glucuronidation/metabolism interference via co-administration of curcumin with adjuvants like piperine; (iii) Nanoparticles and (iv) Emulsifying or dispersing agents. Below, some of the studies on these forms of curcumin in melanoma are summarized.

In a study, Lo *et al.* reported that two compounds namely, 1,7-bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one (BHPHTO) and bisdemethoxycurcumin (BDMC) can inhibit the proliferation of melanoma cells.¹¹² Moreover, Faião-Flores *et al.* revealed that curcumin analogue DM-1, alone or in combination with dacarbazine (DTIC), shows anti-tumor effects as it

Table 2. Various curcumin analogs in melanoma therapy

Type of curcumin	Dose	Target gene	Model (in vitro/ in vivo/human)	Type of cell line	Ref
Tetrahydrocurcumin	Dependent manner	–	<i>In vitro, in vivo</i>	B16F-10	116
Salicyl curcumin	Dependent manner	–	<i>In vitro, in vivo</i>	B16F-10	116
Curcumin III	Dependent manner	–	<i>In vitro, in vivo</i>	B16F-10	116
D6	17.5 mg/kg	Caspase-3 and 7	<i>In vitro, in vivo</i>	LB24, CN-MelA, GR-Mel, WM266-4, 1 3443, M14	114
Curcumin ferrocenyl derivatives	17.9 μ M	–	<i>In vitro</i>	B16	117
(2E,6E)-2,6-bis (2,5-Dimethoxybenzylidene) cyclohexanone	50 μ M	tyrosinase,	<i>In vitro</i>	B16	118
Curcumin- 13c	20 μ M	FGF-R1, EGFR, Btk, Mink, Ret, Itk	<i>In vitro, in vivo</i>	B16F10	119
Curcumin- compound C5	0.71 μ g/ml	Tubulin polymerization inhibitory	<i>In vitro</i>	B16-F10	120
DM-1	5 μ M	TNF-R1, caspase 8	<i>In vitro, in vivo</i>	B16F10, A375	113
DM-1	75 μ M	Mcl-1, Bcl-xL	<i>In vitro</i>	SK-MEL-5 and A375	121
FLLL32/62	2 μ M or 4 μ M	STAT3	<i>In vitro</i>	A375, HT144 Hs294T	122,123
D6	270 nM	p53, PI3K/Akt, NF- κ B	<i>In vitro, in vivo</i>	LB24Dagi	124
Gercumin II	250 μ M	–	<i>In vitro</i>	SK-MEL-28	125
Bisdemethoxycurcumin (BDMC)	25–100 μ M	–	<i>In vitro</i>	A2058, B16-F10	112
Deketene curcumin	20 μ M	G2 arrest	<i>In vitro</i>	B78H1	115
Curcumin-biphenyl derivatives	1, 10 μ M	–	<i>In vitro</i>	WM266, CN, LB24Dagi, PNP	126
DM-1	83 μ M	Caspase-3, –8 and –9	<i>In vitro, in vivo</i>	B16F10	35
NC 2067	2.0–2.4 μ M	–	<i>In vitro</i>	A375	127

inhibited melanoma progression in a melanoma mouse model.¹¹³ In addition, no toxicological changes were observed in organs such as the spleen, kidneys, liver and lungs after the administration of DM-1, either alone or in combination with DTIC. DM-1 in combination with DTIC improved the recovery from anemia induced by melanoma and immunomodulation. It was found that DM-1 alone and in combination with DTIC induces apoptosis via the cleavage of caspase-8, –3 and –9. These results indicated that DM-1 shows therapeutic effects on melanoma via a preferential intrinsic apoptotic pathway by decreasing Bcl-2/Bax ratio.¹¹³

In another study, Pisano *et al.* indicated that D6, a curcumin analogue, has anti-tumor activity against melanoma and neuroblastoma cells.¹¹⁴ This study revealed that α,β -unsaturated ketone D6 shows stronger therapeutic effects in inhibiting melanoma growth in comparison with curcumin. Various experiments were done in this study such as clonogenic assay, TUNEL assay, annexin-V staining and caspases activation assay, and PARP cleavage assay. These experiments confirmed that D6 is more effective in the treatment of melanoma and neuroblastoma when compared with curcumin.

Hence, this data suggested that D6 can be considered as a good candidate for new therapies against neural crest-derived tumors.¹¹⁴

Dahmke *et al.* reported that “deketene curcumin” shows better therapeutic effects than curcumin on melanoma cells.¹¹⁵ This form of curcumin could induce toxicity in B78H1 melanoma cells that finally lead to G2 arrest. Their results confirmed that deketene curcumin can be used as an anti-cancer agent that possesses better bioavailability than curcumin.¹¹⁵

Novel Therapeutic Approaches for Curcumin Targeting in Melanoma

Various studies on bio-distribution, absorption, elimination and metabolism of curcumin have indicated that this agent has rapid metabolism, poor absorption and rapid elimination from the body. Therefore, low systemic bioavailability of oral curcumin is known as a major limitation of its use.¹²⁸ However, it should be considered that many of the metabolites and degradation products of curcumin, possess strong biological and pharmacological activities.^{48–50}

Several studies utilized different approaches to overcome the aforementioned limitations. Using adjuvants can be a suitable approach to block curcumin metabolic pathways and improve its bioavailability.¹²⁹ Various delivery systems such as liposomes, nanoparticles, micelles and phospholipid complexes have been proposed to improve the pharmacokinetic properties of curcumin for cancer therapy. For example, micelles and phospholipid complexes can improve the gastrointestinal absorption of curcumin which results in higher plasma levels.¹²⁹ Another strategy is to enhance the aqueous solubility of curcumin. Recently, Kurien *et al.* reported enhancement of the solubility of curcumin in water by 35 folds by heat under pressure. Interestingly, heat-solubilized curcumin was shown to increase pharmacological effect of curcumin in mice with systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS).¹³⁰ This finding is in line with previous studies showing enhanced solubility and biological activity of heat-treated curcumin.^{131–45} Table 3 illustrates novel curcumin delivery systems used in melanoma therapy. In a study, Lu *et al.* showed that curcumin micelles remodel tumor microenvironment and enhance vaccination efficacy in a model of advanced melanoma. In this study, an amphiphilic curcumin-based micelle (curcumin-PEG conjugate; CUR-PEG) was intravenously administered to a mouse model of melanoma.³⁰ Their results indicated that CUR-PEG and vaccine treatments have a stronger anti-tumor effect compared with separate treatments. Their study showed that utilization of combination therapy leads to significant IFN- γ production (7-fold increase) and cytotoxic T cell response ($41.0 \pm 5.0\%$ specific killing). Moreover, in the tumor microenvironment, these therapies led to significantly downregulated levels of immunosuppressive factors including myeloid-derived suppressor cells (MDSCs), T-reg cells and IL-6, while increased CD8⁺ T cell population. It has been observed that some pro-inflammatory cytokines such as TNF- α and IFN- γ have different expressions in the tumor microenvironment. The aforementioned combination therapies could switch macrophage polarization to M1 phenotype and downregulate the STAT3 pathway in the treated tumors. It was found that CUR-PEG can improve the effects of immunotherapy in melanoma. Novel generations of drug delivery systems such as nanoparticle (NP) technology have provided promising solutions to improve the bioavailability of therapeutic agents. This delivery system will probably be suitable for hydrophobic agents like curcumin that have low aqueous solubility.³⁰

In another study, the effect of dipeptide nanoparticles of curcumin on melanoma was evaluated.¹³³ A nonprotein amino acid, α , β -dehydro-phenylalanine, was used to entrap curcumin in the dipeptide NPs, and the anti-tumor effects of dipeptide-curcumin NPs were assessed in cancer models *in vitro* and *in vivo*. Using different dehydro-dipeptides, it was found that methionine-dehydro-phenylalanine can be regarded as a suitable dehydro-dipeptide for loading and releasing curcumin. In the mentioned study, it was revealed that loading curcumin in dipeptide NPs can improve its cel-

lular availability and solubility, increase its toxicity in various cancer cell lines, and improve curcumin's efficacy in inhibiting tumor growth in mice bearing melanoma tumor. Curcumin-dipeptide NPs also showed enhanced *in vitro* and *in vivo* chemotherapeutic effects compared with free unformulated curcumin. These delivery systems have several advantages as they are highly biocompatible and easy to make, and possess a suitable capacity of loading and releasing curcumin. Moreover, curcumin's cellular uptake is improved with dipeptide NPs.¹³³

In another study, Loch-Neckel *et al.* examined the effect of orally administered chitosan-coated polycaprolactone NPs containing curcumin on metastatic melanoma in the lungs.³⁶ Their results indicated that curcumin could decrease cell viability and induce apoptosis in B16F10 melanoma cells. They found that curcumin significantly reduces the expression of metalloproteinases in melanoma cells. Several studies showed that metalloproteinases are associated with the proliferation and migration of melanoma cells. The utilization of chitosan-coated NPs containing curcumin decreased pulmonary tumor formation in a melanoma lung metastasis model. In addition, histological analyses indicated a few small nodules of melanoma in lungs of mice treated with this system. Hence, curcumin-containing chitosan-coated polycaprolactone NPs may be a suitable system for the treatment of malignant melanoma.³⁶

Curcumin and MicroRNAs in Melanoma

MicroRNAs (miRNAs) are known as small and noncoding RNAs that can suppress gene expression at post-transcriptional levels via sequence-specific interactions with the 3'-untranslated regions (UTRs) of cognate mRNA targets.^{149,150} In addition, miRNAs are involved in the regulation of various key cellular processes such as apoptosis, proliferation, differentiation and development.^{150–153} Alterations in miRNA expression have been observed in a number of cancers, including melanoma. These alterations can arise from either genetic or epigenetic changes.¹⁵⁴ It has been suggested that dietary components may modulate miRNA expression.¹⁵⁵ Few studies have investigated the effect of curcumin on the expression of miRNAs in melanoma. Table 4 illustrates various miRNAs affected by curcumin in different cancers.

Dahmke *et al.* revealed that curcumin intake can affect miRNAs in murine melanoma. They indicated that miR-205-5p was the most significantly altered miRNA.³⁸ This latter study showed that oral administration of curcumin can influence the miRNA signature of engrafting melanoma. Dahmke *et al.* evaluated the effects of curcumin in a melanoma model, which was established by the injection of murine B78H1 cells in the flank of C57BL/6 mice. Curcumin-containing diet (4%) was administered two weeks prior to the injection of tumor cells until the end of the experiment. The results indicated that curcumin feeding significantly decreases the growth of the flank tumors and substantially alters miRNA

Table 3. Novel curcumin delivery systems in melanoma therapy

Type of curcumin	Dose	Target gene	Model (in vitro/in vivo/human)	Type of cell line	Ref
Curcuminbased micelle	–	IL-6, CCL2, TNF- α , IFN- γ	<i>In vitro, in vivo</i>	B16F10	30
Curcumin -FAP α c - CpG		Indolamine-2,3-dioxygenase	<i>In vitro, in vivo</i>	B16	53
Curcumin- RGD-PEG-PLA	–	–	<i>In vitro</i>	B16	52
Chitosan-coated liposomes-containing curcumin	2.5 μ M	–	<i>In vitro</i>	B16F10	134
Curcumin – ANPs					135
Methionine-dehydro-phenylalanine-curcumin NPs	30 μ M	–	<i>In vitro, in vivo</i>	B6F10	133
Curcumin-RGD-IpNPs	25 mg/kg	–	<i>In vitro, in vivo</i>	B16	136
Curcumin-loaded SPC liposomes	20 mg/kg	–	<i>In vitro</i>	B16-F10	137
Curcumin- MBCSPs	500 μ g/ml	–	<i>In vitro, in vivo</i>	B16F10	138
Curcumin- β -Cyclodextrin	14 μ M	–	<i>In vitro</i>	A375	139
Curcumin- β -Cyclodextrin-gemini surfactant	14 μ M	–	<i>In vitro</i>	A375	139
Chitosan-coated nanoparticles containing curcumin	100 mM	MMP-2, MMP-9	<i>In vitro, in vivo</i>	B16F10	36
Curcumin/magnetite nanoparticles	66.0 μ M	–	<i>In vitro</i>	B16-F10	140
Curcumin – chitin nanogels	0.1–1.0 mg/ml	–	<i>In vitro</i>	A375	141
Curcumin – HP- β -CD	300 μ g/ml	G2/M stage	<i>In vitro</i>	B16-F10	142
Curcumin – PEO-PCL	10, 80 μ M	–	<i>In vitro, in vivo</i>	B16F10	143
Curcumin – Muc18	167–335 nM	NF- κ B	<i>In vitro, in vivo</i>	B16F10	144
Curcumin plus PDMP	10 μ M	PI3K/AKT	<i>In vitro</i>	WM-115 and B16	145
Curcumin-nano-capsules	6 mg/kg	–	<i>In vitro, in vivo</i>	B16-F10	146
EF-24-FFRmk-fVIIa	1.5 μ M	–	<i>In vitro</i>	RPMI-7951	147
Curcumin – XGO-b-PCL	1–100 μ M	–	<i>In vitro</i>	B16F10	148

FAP: fibroblast activation protein; PEG-PLA: polyethylene glycol-poly(lactic acid); ANPs: albumin nanoparticles; NP: nanoparticle; SPC: soybean phosphatidylcholine; MBCSPs: magnetic-based core-shell particles; HP- β -CD: hydroxypropyl- β -cyclodextrin; PEO-PCL: poly(ethylene oxide)-b-poly(epsilon-caprolactone); PDMP: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol; FFRmk-fVIIa: EF-24-phenylalanine-phenylalanine argininechloromethyl ketone-factor VIIa; XGO-b-PCL: xyloglucan-block-poly(ϵ -caprolactone).

expression signature in tumors. For example, miR-205-5p was expressed over 100 times higher in the treatment groups compared with the control group. MiRNAs can have various targets in melanoma cells. Western blot analyses indicated that some targets such as proliferating cell nuclear antigen (PCNA) and anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) were significantly downregulated in the treatment groups. This study proposed that there are alterations in the miRNA

expression in engrafting curcumin-treated melanoma and miR-205-5p was the most significantly altered miRNA.³⁸

Diphenyldifluoroketone (EF24) is known as a curcumin analogue with anti-tumor effects that are mediated via inducing apoptosis and arresting cell cycle. Zhang *et al.* investigated the effect of EF24 on miR-33b in melanoma cells.¹⁵⁶ They revealed that at noncytotoxic concentrations, EF24 is able to suppress epithelial-to-mesenchymal transition (EMT)

Table 4. MiRNAs affected by curcumin in various cancers

MiRNA	Type of curcumin	Cancer	Expression in cancer	Target gene	Model	Type of cell line	Ref
miR-33b	EF24	Melanoma	Upregulation	E-cadheri, STAT3	<i>In vitro</i>	Lu1205 and A375	156
miR-205-5p	Curcumin	Melanoma	Upregulation	Bcl-2, PCNA	<i>In vitro, In vivo</i>	B78H1	38
miR-21	EF24	Melanoma	Downregulation	NF-κB, JAK-STAT, PTEN, PDCD4	<i>In vitro, In vivo</i>	B16	39
miR-34a	Curcumin	Colorectal	Upregulation	-	<i>In vitro</i>	HCT116, RKO, SW480, SW620, HT29, Caco2	157
miR-27a	Curcumin	Colorectal	Upregulation	-	<i>In vitro</i>	HCT116, RKO, SW480, SW620, HT29, Caco2	157
miR-7/let-7a, b, c, d, miR-26a, miR-101, miR-146a, miR-200b, c	Curcumin/ difluorinated- curcumin	Pancreatic	Upregulation	EZH2, Notch-1, CD44, EpCAM	<i>In vitro</i>	AsPC-1, BxPC-3/AsPC-1 and MiaPaCa-2	158,159
miR-192-5p/215	Curcumin	Lung	Upregulation	P53	<i>In vitro, In vitro</i>	H460, A427	160
miRNA-186*	Curcumin	Lung	Downregulation	caspase-10	<i>In vitro</i>	A549	161
miR-125a-5p	Curcumin	Nasopharyngeal carcinoma	Downregulation	TP53	<i>In vitro</i>	HONE1	162
miR-9	Curcumin	Ovarian	Upregulation	Akt/FOXO1	<i>In vitro</i>	SKOV3	163
miR-205	PLGA-CUR NPs	Prostate	Upregulation	STAT3, AKT, Mcl-1, Bcl-xL	<i>In vivo</i>	LNcaP	164
miR-19	Curcumin	Breast cancer	Upregulation	PTEN, p-AKT, p-IMDM2, p53	<i>In vitro</i>	MCF-7	165
miR-200a/b	Curcumin	Hepatocellular carcinoma	Upregulation	Bcl-2, Bad	<i>In vitro</i>	HepG2, HepI5	166
miR-15a/16-1	Curcumin	Leukemia	Upregulation	WT1	<i>In vitro</i>	K562, HL-60	167
miR-203	Curcumin	Bladder	Upregulation	Akt2, Src	<i>In vitro</i>	T24, J82 and TCCSUP	

PLGA-CUR NPs: poly(lactic-co-glycolic acid)-curcumin nanoparticles.

and cell motility of melanoma cell lines such as A375 and Lu1205. In addition, EF24 suppressed HMGA2 expression at mRNA and protein levels. MiR-33b can directly bind to 3' untranslated region (3'-UTR) of HMGA2 and suppress its expression. It was shown that miR-33b inhibition or HMGA2 over-expression reverts EF24-mediated suppression of EMT. Moreover, EF24 modulates the focal adhesion assembly, Src, FAK and RhoA activation, and HMGA2-dependent actin stress fiber formation via targeting miR-33b. Hence, these results propose that EF24 can suppress melanoma metastasis by upregulating miR-33b and concomitantly decreasing HMGA2 expression.¹⁵⁶

Yang *et al.* confirmed that EF24 targets NF- κ B and miRNA-21, and possesses a promising anti-tumor activity.³⁹ EF24 has been reported to inhibit the NF- κ B pathway in DU145 human prostate cancer cells and B16 murine melanoma cells. Moreover, EF24 induced apoptosis in these cells apparently via inhibiting miR-21 expression, and also improved the expression of several miR-21 target genes, *e.g.*, PDCD4 and PTEN. This molecule inhibited miR-21 expression and lung metastasis, prolonged animal survival and increased the expression of miR-21 target genes in a mouse model of melanoma. Moreover, EF24 enhanced the expression of potential tumor suppressor miRNAs and inhibited the expression of oncogenic miRNAs, such as miR-21. These findings proposed that EF24 shows anti-cancer activities via regulating NF- κ B pathway and miRNA expression.³⁹

Conclusion

Melanoma, a malignant tumor of melanocytes, is one of the most aggressive types of malignancies. Although melanoma comprises <5% of all skin cancers, it is responsible for the

majority of skin cancer-related deaths. At early stages, melanoma can be treated by surgical resection; however, most often it progresses to the invasive stage and does not respond to conventional treatments largely due to the development of multi-drug resistance. Hence, new therapies are required to overcome the limitations of conventional therapies. Several lines of evidence have indicated that curcumin affects key pathways that are involved in different cancers such as melanoma. It seems that this molecule plays an important role in cancer therapy. Several targets at the cellular and molecular levels (*e.g.*, signaling pathways, transcription factors and miRNAs) are affected by curcumin in melanoma. Hence, curcumin can be regarded as a promising agent in the treatment of melanoma. Nevertheless, utilization of curcumin is associated with some limitations such as rapid metabolism, low oral absorption and rapid elimination from the body. These limitations may attenuate efficacy and decrease the therapeutic effects of curcumin. New formulations and novel delivery systems have opened a new window into the landscape of treatment of various diseases such as melanoma with curcumin. Finally, most of the evidence on the efficacy of curcumin against melanoma and other types of cancer pertains to preclinical studies. Although some clinical evidence exists that favors the benefits of curcumin supplementation in cancer patients,^{168–170} clinical evidence is still scarce and a thorough outcome study is yet to be performed. Hence, clinical proof-of-concept investigations are required to verify the translational value of the reported anti-tumor effects of curcumin in animal and cellular models of cancer. However, further evidence from prospective clinical trials is required to decipher the place of curcumin in the clinical management of melanoma.

References

1. Yu T, Chen C, Sun Y, et al. ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway. *Biochem Biophys Res Commun* 2015; 286–91.
2. Thangapazham RL, Sharad S, Maheshwari RK. Skin regenerative potentials of curcumin. *Biofactories* 2013; 39:141–9.
3. Panahi Y, Saadat A, Beiraghdar F, et al. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. *Phytother Res* 2014; 28: 1461–7.
4. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. *Med Chem* 2010; 17:190–7.
5. Sahebkar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant-antioxidant mechanisms. *Nat Prod Res* 2015; 29:491–2.
6. Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. *Chin J Integr Med* 2015; 21:332–8.
7. Sahebkar A, Mohammadi A, Atabati A, et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. *Phytother Res* 2013; 27: 1883–8.
8. Panahi Y, Sahebkar A, Amiri M, et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. *Br J Nutr* 2012; 108: 1272–9.
9. Panahi Y, Ghanei M, Hajhashemi A, et al. Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. *J Diet Suppl* 2016; 13:93–105.
10. Panahi Y, Alishiri GH, Parvin S, et al. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. *J Diet Suppl* 2016; 13:209–20.
11. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. *Phytother Res* 2014; 28:633–42.
12. Panahi Y, Sahebkar A, Parvin S, et al. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. *Ann Clin Biochem* 2012; 49: 580–8.
13. Panahi Y, Hosseini MS, Khalili N, et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. *Clin Nutr* 2015; 34:1101–8.
14. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. *Nat Rev Cardiol* 2014; 11:123.
15. Sahebkar A. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. *Basic Clin Pharmacol Toxicol* 2014; 114:437–8.
16. Panahi Y, Khalili N, Hosseini MS, et al. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. *Complement Ther Med* 2014; 22:851–7.
17. Mohammadi A, Sahebkar A, Iranshahi M, et al. Effects of supplementation with curcuminoids

- on dyslipidemia in obese patients: a randomized crossover trial. *Phytother Res* 2013; 27:374–9.
18. Panahi Y, Rahimnia AR, Sharafi M, et al. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. *Phytother Res* 2014; 28:1625–31.
 19. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? *Bio-Factors* 2013; 39:197–208.
 20. Swamy AV, Gulliyasa S, Thippeswamy A, et al. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. *Indian J Pharmacol* 2012; 44:73–7.
 21. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. *Fertil Steril* 2010; 94:e75–6.
 22. Panahi Y, Badeli R, Karami GR, et al. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. *Phytother Res* 2015; 29:17–21.
 23. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, et al. Curcumin extract for prevention of type 2 diabetes. *Diabetes Care* 2012; 35:2121–7.
 24. Mythri RB, Bharath MM. Curcumin: a potential neuroprotective agent in Parkinson's disease. *Curr Pharm Des* 2012; 18:91–9.
 25. Sahebkar A. Autophagic activation: a key piece of the puzzle for the curcumin-associated cognitive enhancement? *J Psychophar* 2016; 30:93–4.
 26. Jiang Z, Guo M, Shi C, et al. Protection against cognitive impairment and modification of epileptogenesis with curcumin in a post-status epilepticus model of temporal lobe epilepsy. *Neuroscience* 2015; 310:362–71.
 27. Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. *J Psychophar* 2015; 29:642–51.
 28. Shakeri A, Sahebkar A. Optimized curcumin formulations for the treatment of Alzheimer's disease: a patent evaluation. *J Neurosci Res* 2016; 94:111–3.
 29. Hasan ST, Zingg JM, Kwan P, et al. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatitis in LDL receptor deficient mice. *Atherosclerosis* 2014; 232:40–51.
 30. Lu Y, Miao L, Wang Y, et al. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. *Mol Ther* 2016; 24:364–74.
 31. Miller AJ, Mihm MC, Jr. Melanoma. *N Engl J Med* 2006; 355:51–65.
 32. Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. *Oncotarget* 2015; 6:42008–18. Dec 8;:-.
 33. Uzarska M, Czajkowski R, Schwartz RA, et al. Chemoprevention of skin melanoma: facts and myths. *Melanoma Res* 2013; 23:426–33.
 34. Akabane H, Sullivan RJ. The future of molecular analysis in melanoma: diagnostics to direct molecularly targeted therapy. *Am J Clin Dermatol* 2016; 17:1–10.
 35. Faiao-Flores F, Quincoces Suarez JA, Fruet AC, et al. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression. *PLoS One* 2015; 10:e0118702
 36. Loch-Neckel G, Santos-Bubniak L, Mazzarino L, et al. Orally administered chitosan-coated polycaprolactone nanoparticles containing curcumin attenuate metastatic melanoma in the lungs. *J Pharm Sci* 2015; 104:3524–34.
 37. Nguyen TA, Friedman AJ. Curcumin: a novel treatment for skin-related disorders. *J Drugs Dermatol* 2013; 12:1131–7.
 38. Dahmke IN, Backes C, Rudzitis-Auth J, et al. Curcumin intake affects miRNA signature in murine melanoma with mmu-miR-205-5p most significantly altered. *PLoS One* 2013; 8:e81122
 39. Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NF- κ B and miRNA-21, and has potent anticancer activity in vitro and in vivo. *PLoS One* 2013; 8:e71130
 40. Li XJ, Li YZ, Jin CT, et al. Curcumin induces apoptosis by PTEN/PI3K/AKT pathway in EC109 cells. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 2015; 31:174–7.
 41. Bhavani Shankar T, Shantha N, Ramesh H, et al. Toxicity studies on turmeric (*Curcuma longa*): acute toxicity studies in rats, guinea pigs and monkeys. *Indian J Exp Biol* 1980; 18:73–5.
 42. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med* 2006; 6:10
 43. Zhang J, Tang Q, Xu X, et al. Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery. *Int J Pharm* 2013; 448:168–74.
 44. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol* 2009; 41:40–59.
 45. Kurien BT, Singh A, Matsumoto H, et al. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. *Assay Drug Dev Technol* 2007; 5:567–76.
 46. Mancuso C, Siciliano R, Barone E. Curcumin and Alzheimer disease: this marriage is not to be performed. *J Biol Chem* 2011; 286:1e3
 47. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. *Mol Pharm* 2007; 4:807–18.
 48. Aggarwal BB, Deb L, Prasad S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. *Molecules* 2015; 20:185–205.
 49. Barone E, Calabrese V, Mancuso C. Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. *Biogerontology* 2009; 10:97–108.
 50. Sultana R. Ferulic acid ethyl ester as a potential therapy in neurodegenerative disorders. *Biochim Biophys Acta* 2012; 1822:748–52.
 51. Kurien BT, Scofield RH. Curcumin/turmeric solubilized in sodium hydroxide inhibits HNE protein modification—an in vitro study. *J Ethnopharmacol* 2007; 110:368–73.
 52. Zhao L, Yang C, Dou J, et al. Development of RGD-functionalized PEG-PLA micelles for delivery of curcumin. *J Biomed Nanotechnol* 2015; 11:436–46.
 53. Jiang GM, Xie WY, Wang HS, et al. Curcumin combined with FAPalpac vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF- α in melanoma. *Oncotarget* 2015; 6:25932–42.
 54. Siwak DR, Shishodia S, Aggarwal BB, et al. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of I κ B kinase and nuclear factor κ B activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. *Cancer Res* 2005; 104:879–90.
 55. Lu C, Song E, Hu DN, et al. Curcumin induces cell death in human uveal melanoma cells through mitochondrial pathway. *Curr Eye Res* 2010; 35:352–60.
 56. Bush JA, Cheung KJ, Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. *Exp Cell Res* 2001; 271:305–14.
 57. Zhang YP, Li YQ, Lv YT, et al. Effect of curcumin on the proliferation, apoptosis, migration, and invasion of human melanoma A375 cells. *Genet Mol Res* 2015; 14:1056–67.
 58. Philip S, Kundu GC. Osteopontin induces nuclear factor κ B-mediated promatrix metalloproteinase-2 activation through I κ B α /IKK signaling pathways, and curcumin (diferuloylmethane) down-regulates these pathways. *J Biol Chem* 2003; 278:14487–97.
 59. McCarthy MM, Pick E, Kluger Y, et al. HSP90 as a marker of progression in melanoma. *Ann Oncol* 2008; 19:590–4.
 60. Miyagawa T, Saito H, Minamiya Y, et al. Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature. *Int J Clin Oncol* 2014; 19:722–30.
 61. Fang BM, Jiang JH, Zhang XW, et al. Curcumin enhances bortezomib treatment of myeloma by inhibiting heat shock protein 90 expression. *Trop J Pharm Res* 2015; 14:227–33.
 62. Calabrese V, Guagliano E, Sapienza M, et al. Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. *Neurochem Res* 2007; 32:757–73.
 63. Mancuso C, Scapagini G, Curro D, et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. *Front Biosci* 2007; 12:1107–23.
 64. Mancuso C, Santangelo R, Calabrese V. The heme oxygenase/biliverdin reductase system: a potential drug target in Alzheimer's disease. *J Biol Reg Homeos Ag* 2012; 27:75–87.
 65. Arena V, Pennacchia I, Guerriero G, et al. The heme oxygenase/biliverdin reductase system in skin cancers. *J Biol Reg Homeos Ag* 2014; 29:259–64.
 66. Calabrese V, Bates TE, Mancuso C, et al. Curcumin and the cellular stress response in free radical-related diseases. *Mol Nutr Food Res* 2008; 52:1062–73.
 67. Goodpasture C, Arrighi F. Effects of food seasonings on the cell cycle and chromosome morphology of mammalian cells in vitro with special reference to turmeric. *Food Cosmet Toxicol* 1976; 14:9–14.
 68. Giri A, Das SK, Talukder G, et al. Sister chromatid exchange and chromosome aberrations induced by curcumin and tartrazine on mammalian cells in vivo. *Cytobios* 1989; 62:111–7.
 69. Burgos-Morón E, Calderón-Montaño JM, Salvador J, et al. The dark side of curcumin. *Int J Cancer* 2010; 126:1771–5.
 70. Kurien BT, Dillon SP, Dorri Y, et al. Curcumin does not bind or intercalate into DNA and a

- note on the gray side of curcumin. *Int J Cancer* 2011; 128:242–5.
71. Mancuso C, Barone E. Curcumin in clinical practice: myth or reality? *Trends Pharmacol Sci* 2009; 30:333–4.
 72. Yu T, Chen C, Sun Y, et al. ABT-737 sensitizes curcumin-induced anti-mitochondrial cell activity through facilitating mPTP death pathway. *Biochem Biophys Res Commun* 2015; 464:286–91.
 73. Wolnicka-Glubisz A, Nogal K, Zadło A, et al. Curcumin does not switch melanin synthesis towards pheomelanin in B16F10 cells. *Arch Dermatol Res* 2015; 307:89–98.
 74. Jiang AJ, Jiang G, Li LT, et al. Curcumin induces apoptosis through mitochondrial pathway and caspases activation in human melanoma cells. *Mol Biol Rep* 2015; 42:267–75.
 75. Oelkrug C, Lange CM, Wenzel E, et al. Analysis of the tumoricidal and anti-cachectic potential of curcumin. *Anticancer Res* 2014; 34:4781–8.
 76. Chen J, Li L, Su J, et al. Synergistic apoptosis-inducing effects on A375 human melanoma cells of natural borneol and curcumin. *PLoS One* 2014; 9:e101277
 77. Qiu Y, Yu T, Wang W, et al. Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. *Biochem. Biophys Res Commun* 2014; 448:15–21.
 78. Buss S, Dobra J, Goerg K, et al. Visible light is a better co-inducer of apoptosis for curcumin-treated human melanoma cells than UVA. *PLoS One* 2013; 8:e79748
 79. Yu T, Ji J, Guo YL. MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. *Biochem Biophys Res Commun* 2013; 441:53–8.
 80. Attaoua C, Vincent LA, Abdel Jaoued A, et al. Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids. *Fundam Clin Pharmacol* 2015; 29:62–71.
 81. Shiau RJ, Wu JY, Chiou SJ, et al. Effects of curcumin on nitrosyl-iron complex-mediated DNA cleavage and cytotoxicity. *Planta Med* 2012; 78:1342–50.
 82. Chakraborty G, Kumar S, Mishra R, et al. Semaforin 3A suppresses tumor growth and metastasis in mice melanoma model. *PLoS One* 2012; 7:e33633
 83. Abusnina A, Keravis T, Youbare I, et al. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. *Mol Nutr Food Res* 2011; 55:1677–89.
 84. Park SY, Jin ML, Kim YH, et al. Aromatic-turmerone inhibits alpha-MSH and IBMX-induced melanogenesis by inactivating CREB and MITF signaling pathways. *Arch Dermatol Res* 2011; 303:737–44.
 85. Prakash M, Kale S, Ghosh I, et al. Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin alpha(v)beta(3) interaction. *Cell Signal* 2011; 23:1563–77.
 86. Tu CX, Lin M, Lu SS, et al. Curcumin inhibits melanogenesis in human melanocytes. *Phytother Res* 2012; 26:174–9.
 87. Chatterjee SJ, Pandey S. Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. *Cancer Biol Ther* 2011; 11:216–28.
 88. Chen LX, He YJ, Zhao SZ, et al. Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. *Cancer Biol Ther* 2011; 11:229–35.
 89. Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. *Mol Ther* 2010; 18:1606–14.
 90. Lee JH, Jang JY, Park C, et al. Curcumin suppresses alpha-melanocyte stimulating hormone-stimulated melanogenesis in B16F10 cells. *Int J Mol Med* 2010; 26:101–6.
 91. Wang L, Shen Y, Song R, et al. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. *Mol Pharmacol* 2009; 76:1238–45.
 92. Bill MA, Bakan C, Benson DM, Jr, et al. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. *Mol Cancer Ther* 2009; 8:2726–35.
 93. Purkayastha S, Berliner A, Fernando SS, et al. Curcumin blocks brain tumor formation. *Brain Res* 2009; 1266:130–8.
 94. Gui F, Ma WF, Cai SH, et al. Preliminary study on molecular mechanism of curcumin anti-mouse melanoma. *Zhongyaocai* 2008; 31:1685–9.
 95. Bakhshi J, Weinstein L, Poksay KS, et al. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. *Apoptosis* 2008; 13:904–14.
 96. Marin YE, Wall BA, Wang S, et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. *Melanoma Res* 2007; 17:274–83.
 97. Qiu S, Tan SS, Zhang JA, et al. Apoptosis induced by curcumin and its effect on c-myc and caspase-3 expressions in human melanoma A375 cell line. *Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA* 2005; 25:1517–21.
 98. Depelle P, Cuq P, Passagne I, et al. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. *Br J Cancer* 2005; 93:216–23.
 99. Odot J, Albert P, Carlier A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. *Int J Cancer* 2004; 111:381–7.
 100. Banerji A, Chakrabarti J, Mitra A, et al. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. *Cancer Lett* 2004; 211:235–42.
 101. Zheng M, Ekmekcioglu S, Walch ET, et al. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. *Melanoma Res* 2004; 14:165–71.
 102. Depelle P, Cuq P, Mary S, et al. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. *Mol Pharmacol* 2004; 65:897–905.
 103. Ray S, Chattopadhyay N, Mitra A, et al. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. *J Environ Pathol Toxicol Oncol* 2003; 22:49–58.
 104. Ramsewak RS, DeWitt DL, Nair MG. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from *Curcuma longa*. *Phyto-medicine* 2000; 7:303–8.
 105. Iersel ML, Ploemen JP, Struik I, et al. Inhibition of glutathione S-transferase activity in human melanoma cells by alpha, beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. *Chem Biol Interact* 1996; 102:117–32.
 106. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. *Cancer Lett* 1995; 95:221–5.
 107. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. *Eur J Cancer* 2005; 41:1955–68.
 108. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. *Ann N Y Acad Sci* 2005; 1056:206–17.
 109. Chen JW, Tang YL, Liu H, et al. Anti-proliferative and anti-metastatic effects of curcumin on oral cancer cells. *WCJS* 2011; 29:83–6
 110. Waghela BN, Sharma A, Dhumale S, et al. Curcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cells. *PLoS One* 2015; 10:e0117526
 111. Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. *Biochem Pharmacol* 2008; 76:1590–611.
 112. Lo CY, Liu PL, Lin LC, et al. Antimelanoma and antityrosinase from *Alpinia galangal* constituents. *Scientific World J* 2013; 2013:186505
 113. Faiao-Flores F, Suarez JA, Maria-Engler SS, et al. The curcumin analog DM-1 induces apoptotic cell death in melanoma. *Tumour* 2013; 34:1119–29.
 114. Pisano M, Pagnan G, Dettori MA, et al. Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. *Mol Cancer* 2010; 9:137
 115. Dahmke IN, Boettcher SP, Groh M, et al. Cooking enhances curcumin anti-cancerogenic activity through pyrolytic formation of "deketed curcumin". *Food Chem* 2014; 151:514–9.
 116. Leyon PV, Kuttan G. Studies on the role of some synthetic curcuminoid derivatives in the inhibition of tumour specific angiogenesis. *J Exp Clin Cancer Res* 2003; 22:77–83.
 117. Arezki A, Chabot G, Quentin L, et al. Synthesis and biological evaluation of novel ferrocenyl curcuminoid derivatives. *Med Chem Commun* 2011; 2:190–5.
 118. Hosoya T, Nakata A, Yamasaki F, et al. Curcumin-like diarylpentanoid analogues as melanogenesis inhibitors. *J Nat Med* 2012; 66:166–76.
 119. Lamoral-Theys D, Wauthoz N, Heffeter P, et al. Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca²⁺ release. *J Cell Mol Med* 2012; 16:1421–34.
 120. Ruan BF, Lu X, Li TT, et al. Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents. *Bioorg Med Chem* 2012; 20:1113–21.
 121. Faiao-Flores F, Suarez JA, Soto-Cerrato V, et al. Bcl-2 family proteins and cytoskeleton changes

- involved in DM-1 cytotoxic effect on melanoma cells. *Tumour Biol* 2013; 34:1235–43.
122. Bill MA, Fuchs JR, Li C, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. *Mol Cancer* 2010; 9:165
 123. Bill MA, Nicholas C, Mace TA, et al. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. *PLoS One* 2012; 7:e40724
 124. Rozzo C, Fanciulli M, Fraumene C, et al. Molecular changes induced by the curcumin analogue D6 in human melanoma cells. *Mol Cancer* 2013; 12:37
 125. Valiahdi SM, Iranshahi M, Sahebkar A. Cytotoxic activities of phytochemicals from *Ferula* species. *DARU* 2013; 21:39
 126. Dettori MA, Fabbri D, Pisano M, et al. 4-substituted-2-methoxyphenol: suitable building block to prepare new bioactive natural-like hydroxylated biphenyls. *Lett Drug Des Discov* 2015; 12: 131–9.
 127. Poorghorban M, Das U, Alaidi O, et al. Characterization of the host-guest complex of a curcumin analog with beta-cyclodextrin and beta-cyclodextrin-gemini surfactant and evaluation of its anticancer activity. *Int J Nanomedicine* 2015; 10:503–15.
 128. Kidd PM. Bioavailability and activity of phyto-some complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. *Altern Med Rev* 2009; 14:226–46.
 129. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. *Cancer Res Treat* 2014; 46:2–18.
 130. Kurien BT, Harris VM, Quadri SM, et al. Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-*lpr/lpr* mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment. *Lupus Sci Med* 2015; 2:e000114
 131. Kurien BT, Scofield RH. Oral administration of heat-solubilized curcumin for potentially increasing curcumin bioavailability in experimental animals. *Int J Cancer* 2009; 125:1992–3.
 132. Kurien BT, Scofield RH. Heat-solubilized curcumin should be considered in clinical trials for increasing bioavailability. *Clin Cancer Res* 2009; 15:747
 133. Alam S, Panda JJ, Chauhan VS. Novel dipeptide nanoparticles for effective curcumin delivery. *Int J Nanomedicine* 2012; 7:4207–22.
 134. Karczmarczuk A, Bielska D, Loboda A, et al. Curcumin-containing liposomes stabilized by thin layers of chitosan derivatives. *Colloids Surf B Biointerfaces* 2013; 109:307–16.
 135. Cui M, Naczynski DJ, Zevon M, et al. Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. *Adv Healthc Mater* 2013; 2:1236–45.
 136. Zhao Y, Lin D, Wu F, et al. Discovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug delivery. *Int J Mol Sci* 2014; 15:17565–76.
 137. Chen Y, Wu Q, Zhang Z, et al. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. *Molecules* 2012; 17:5972–87.
 138. Wadajkar AS, Bhavsar Z, Ko CY, et al. Multifunctional particles for melanoma-targeted drug delivery. *Acta Biomater* 2012; 8:2996–3004.
 139. Michel D, Chitanda JM, Balogh R, et al. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma. *Eur J Pharm Biopharm* 2012; 81:548–56.
 140. de Souza FF, dos Santos MC, dos Passos DC, et al. Curcumin associated magnetite nanoparticles inhibit in vitro melanoma cell growth. *J Nanosci Nanotechnol* 2011; 11:7603–10.
 141. Mangalathillam S, Rejinold NS, Nair A, et al. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. *Nanoscale* 2012; 4:239–50.
 142. Sun Y, Du L, Liu Y, et al. Transdermal delivery of the in situ hydrogels of curcumin and its inclusion complexes of hydroxypropyl-beta-cyclodextrin for melanoma treatment. *Int J Pharm* 2014; 469:31–9.
 143. Ma Z, Haddadi A, Molavi O, et al. Micelles of poly(ethylene oxide)-*b*-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. *J Biomed Mater Res A* 2008; 86:300–10.
 144. Langone P, Debata PR, Dolai S, et al. Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin. *Int J Cancer* 2012; 131:E569–78.
 145. Yu T, Li J, Qiu Y, et al. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation. *Mol Cell Biochem* 2012; 361:47–54.
 146. Mazzarino L, Silva LF, Curta JC, et al. Curcumin-loaded lipid and polymeric nanocapsules stabilized by nonionic surfactants: an in vitro and in vivo antitumor activity on B16-F10 melanoma and macrophage uptake comparative study. *J Biomed Nanotechnol* 2011; 7:406–14.
 147. Sun A, Shoji M, Lu YJ, et al. Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. *J Med Chem* 2006; 49:3153–8.
 148. Mazzarino L, Otsuka I, Halila S, et al. Xyloglucan-block-poly(ϵ -caprolactone) copolymer nanoparticles coated with chitosan as biocompatible mucoadhesive drug delivery system. *Macromol Biosci* 2014; 14:709–19.
 149. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell* 2009; 136:215–33.
 150. Mirzaei H, Gholamin S, Shahidsales S, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. *Eur J Cancer* 2016; 53:25–32.
 151. Schickel R, Boyerinas B, Park SM, et al. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. *Oncogene* 2008; 27:5959–74.
 152. Salarini R, Sahebkar A, Mirzaei H, et al. Epi-drugs and epi-miRs: moving beyond current cancer therapies. *Curr Cancer Drug Targets* 2015.
 153. Gholamin S, Pasdar A, Khorrami M, et al. The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment. *Curr Pharm Des* 2016; 22:397–403.
 154. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. *Cell* 2009; 136: 586–91.
 155. Saini S, Majid S, Dahiya R. Diet, microRNAs and prostate cancer. *Pharmaceut Res* 2010; 27: 1014–26.
 156. Zhang P, Bai H, Liu G, et al. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2. *Toxicol Lett* 2015; 234:151–61.
 157. Toden S, Okugawa Y, Buhmann C, et al. Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. *Cancer Prev Res (Phila)* 2015; 8:431–43.
 158. Sadeghipour A, Eidi M, Ilchizadeh Kavani A, et al. Lipid lowering effect of punica granatum L. Peel in high lipid diet fed male rats. *Evid Based Complement Alternat Med* 2014; 2014:432650
 159. Ali S, Ahmad A, Aboukameel A, et al. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. *Cancer Lett* 2012; 319:17381.
 160. Ye M, Zhang J, Zhang J, et al. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. *Cancer Lett* 2015; 357:196–205.
 161. Zhang J, Du Y, Wu C, et al. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. *Oncol Rep* 2010; 24:1217–23.
 162. Gao W, Chan JY, Wong TS. Curcumin exerts inhibitory effects on undifferentiated nasopharyngeal carcinoma by inhibiting the expression of miR-125a-5p. *Clin Sci* 2014; 127:571–9.
 163. Zhao SF, Zhang X, Zhang XJ, et al. Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells. *APJCP* 2014; 15:3363–8.
 164. Yallapu MM, Khan S, Maher DM, et al. Anticancer activity of curcumin loaded nanoparticles in prostate cancer. *Biomaterials* 2014; 35:8635–48.
 165. Li X, Xie W, Xie C, et al. Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. *Phytother. Res* 2014; 28:1553–60.
 166. Liang HH, Wei PL, Hung CS, et al. MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. *Tumour Biol* 2013; 34:3209–18.
 167. Gao SM, Yang JJ, Chen CQ, et al. Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. *JECCR* 2012; 31:27
 168. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res* 2008; 14:4491–9.
 169. Mahammedi H, Planchat E, Pouget M, et al. The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study. *Oncology* 2016; 90:69–78.
 170. Hejazi J, Rastmanesh R, Taleban FA, et al. Effect of curcumin supplementation during radiotherapy on oxidative status of patients with prostate cancer: a double blinded, randomized, placebo-controlled study. *Nutr Cancer* 2016; 68:77–85.